Novaferon

Summary

Novaferon (CHEMBL4650410) is a phase-3 clinical-stage unknown; indicated across 4 conditions including severe acute respiratory syndrome and neuroendocrine neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650410
Name	Novaferon
Type	Unknown
Max phase	3

Also known as: Nova (artificial interferon), Novaferon, NOVAFERON

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
breast carcinoma	1	MONDO:0004989	EFO:0000305
hepatocellular carcinoma	1	MONDO:0007256	EFO:0000182

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04669015	PHASE3	UNKNOWN	Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19
NCT04708158	PHASE3	UNKNOWN	Novaferon for COVID-19 Treatment Trial (NCTT-005)
NCT05172037	PHASE3	UNKNOWN	Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
NCT04380545	PHASE1/PHASE2	RECRUITING	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
NCT02068131	PHASE2	UNKNOWN	Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer
NCT04418219	PHASE1/PHASE2	WITHDRAWN	Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).